Arbutus Biopharma

ABUS

Arbutus Biopharma Corporation is a publicly traded (NASDAQ: ABUS) biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection.It is headquartered in Vancouver, British Columbia and has research facilities in Warminster, Pennsylvania. The company was formerly known as Tekmira, which was spun out of Inex Pharmaceuticals in 2007.

Arbutus Biopharma has been a target of short sellers for a while. The current short interest of 9.55% is roughly at the average of the last 12 months (7.57%).